Capital International Sarl Raises Stock Holdings in Icon Plc $ICLR

Capital International Sarl increased its position in Icon Plc (NASDAQ:ICLR) by 503.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 51,219 shares of the medical research company’s stock after buying an additional 42,727 shares during the quarter. Capital International Sarl owned 0.06% of Icon worth $9,333,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Muhlenkamp & Co. Inc. purchased a new stake in shares of Icon in the 3rd quarter worth about $12,857,000. Mitchell Capital Management Co. purchased a new stake in shares of Icon in the 3rd quarter worth about $1,627,000. First National Bank of Omaha purchased a new stake in shares of Icon in the 3rd quarter worth about $6,267,000. Allspring Global Investments Holdings LLC grew its position in shares of Icon by 1.1% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,080,192 shares of the medical research company’s stock worth $203,800,000 after buying an additional 11,335 shares during the period. Finally, CIBC Bancorp USA Inc. purchased a new stake in shares of Icon in the 3rd quarter worth about $39,074,000. 95.61% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ICLR has been the topic of a number of recent research reports. TD Cowen upped their target price on shares of Icon from $120.00 to $164.00 and gave the stock a “buy” rating in a research report on Monday, June 1st. Zacks Research downgraded shares of Icon from a “hold” rating to a “strong sell” rating in a research report on Wednesday, February 25th. Bank of America reaffirmed an “outperform” rating on shares of Icon in a research report on Monday, June 1st. Jefferies Financial Group reaffirmed a “buy” rating and issued a $165.00 target price on shares of Icon in a research report on Friday, May 29th. Finally, Royal Bank Of Canada upped their price target on shares of Icon from $123.00 to $126.00 and gave the stock a “sector perform” rating in a research note on Friday, May 29th. Eight analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $156.44.

Icon Stock Performance

Shares of Icon stock opened at $149.45 on Monday. The stock has a market cap of $11.44 billion, a price-to-earnings ratio of 24.26, a PEG ratio of 11.81 and a beta of 1.26. The firm’s 50-day moving average is $117.51 and its 200 day moving average is $140.74. Icon Plc has a 1 year low of $66.57 and a 1 year high of $211.00. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.10 and a quick ratio of 1.10.

Icon (NASDAQ:ICLR) last announced its quarterly earnings results on Wednesday, May 27th. The medical research company reported $2.21 earnings per share (EPS) for the quarter. The company had revenue of $2.11 billion for the quarter. Icon had a net margin of 5.98% and a return on equity of 9.50%. Icon has set its FY 2026 guidance at 10.000-11.000 EPS. Sell-side analysts anticipate that Icon Plc will post 9.74 EPS for the current fiscal year.

Icon Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.